Cargando…
Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy
The transfusion transmission of hepatitis C and HIV to thousands of Canadian blood recipients was one of this country's largest public health catastrophes. In response to this crisis, and in an effort to prevent such a tragedy from occurring again, the Canadian blood system has undergone substa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126723/ https://www.ncbi.nlm.nih.gov/pubmed/17014945 http://dx.doi.org/10.1016/j.socscimed.2006.08.023 |
_version_ | 1783516208179445760 |
---|---|
author | Wilson, Kumanan Graham, Ian Ricketts, Maura Dornan, Christopher Laupacis, Andreas Hebert, Paul |
author_facet | Wilson, Kumanan Graham, Ian Ricketts, Maura Dornan, Christopher Laupacis, Andreas Hebert, Paul |
author_sort | Wilson, Kumanan |
collection | PubMed |
description | The transfusion transmission of hepatitis C and HIV to thousands of Canadian blood recipients was one of this country's largest public health catastrophes. In response to this crisis, and in an effort to prevent such a tragedy from occurring again, the Canadian blood system has undergone substantial reform. Variant Creutzfeldt–Jakob (vCJD) disease was the first infectious threat faced by the blood system since undergoing reform. The response at the time to this risk provides insights into the Canadian blood system's new approach to infectious threats. Our analysis of the decision-making concerning vCJD identifies two dominant themes characterizing the new blood system's approach to safety: (1).. the adoption of a precautionary approach to new risks which involves taking action in advance of definitive evidence, and (2).. risk aversion amongst policy makers, which has contributed to the adoption of safety measures with comparatively high cost-effectiveness ratios. Overall the principles governing the new blood system have contributed to the system both providing protection against emerging infectious risks and regaining the confidence of the public and recipients. However, the current set of policy factors will likely contribute to increasingly risk-averse policy making that will contribute to continued increases in the cost of the blood system. The challenge the blood system now faces is to find the appropriate balance between maximizing safety and ensuring the system remains affordable. |
format | Online Article Text |
id | pubmed-7126723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71267232020-04-08 Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy Wilson, Kumanan Graham, Ian Ricketts, Maura Dornan, Christopher Laupacis, Andreas Hebert, Paul Soc Sci Med Article The transfusion transmission of hepatitis C and HIV to thousands of Canadian blood recipients was one of this country's largest public health catastrophes. In response to this crisis, and in an effort to prevent such a tragedy from occurring again, the Canadian blood system has undergone substantial reform. Variant Creutzfeldt–Jakob (vCJD) disease was the first infectious threat faced by the blood system since undergoing reform. The response at the time to this risk provides insights into the Canadian blood system's new approach to infectious threats. Our analysis of the decision-making concerning vCJD identifies two dominant themes characterizing the new blood system's approach to safety: (1).. the adoption of a precautionary approach to new risks which involves taking action in advance of definitive evidence, and (2).. risk aversion amongst policy makers, which has contributed to the adoption of safety measures with comparatively high cost-effectiveness ratios. Overall the principles governing the new blood system have contributed to the system both providing protection against emerging infectious risks and regaining the confidence of the public and recipients. However, the current set of policy factors will likely contribute to increasingly risk-averse policy making that will contribute to continued increases in the cost of the blood system. The challenge the blood system now faces is to find the appropriate balance between maximizing safety and ensuring the system remains affordable. Elsevier Ltd. 2007-01 2006-10-02 /pmc/articles/PMC7126723/ /pubmed/17014945 http://dx.doi.org/10.1016/j.socscimed.2006.08.023 Text en Copyright © 2006 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Wilson, Kumanan Graham, Ian Ricketts, Maura Dornan, Christopher Laupacis, Andreas Hebert, Paul Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy |
title | Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy |
title_full | Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy |
title_fullStr | Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy |
title_full_unstemmed | Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy |
title_short | Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy |
title_sort | variant creutzfeldt–jakob disease and the canadian blood system after the tainted blood tragedy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126723/ https://www.ncbi.nlm.nih.gov/pubmed/17014945 http://dx.doi.org/10.1016/j.socscimed.2006.08.023 |
work_keys_str_mv | AT wilsonkumanan variantcreutzfeldtjakobdiseaseandthecanadianbloodsystemafterthetaintedbloodtragedy AT grahamian variantcreutzfeldtjakobdiseaseandthecanadianbloodsystemafterthetaintedbloodtragedy AT rickettsmaura variantcreutzfeldtjakobdiseaseandthecanadianbloodsystemafterthetaintedbloodtragedy AT dornanchristopher variantcreutzfeldtjakobdiseaseandthecanadianbloodsystemafterthetaintedbloodtragedy AT laupacisandreas variantcreutzfeldtjakobdiseaseandthecanadianbloodsystemafterthetaintedbloodtragedy AT hebertpaul variantcreutzfeldtjakobdiseaseandthecanadianbloodsystemafterthetaintedbloodtragedy |